Ying Gibbens1, Prasad G Iyer2. 1. Department of Medicine, Mayo Clinic, Rochester, Minnesota. 2. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Abstract
PURPOSE OF REVIEW: There is conflicting data on the effectiveness of the currently recommended endoscopic surveillance strategy in non-dysplastic BE patients. We reviewed the literature to evaluate the (cost) effectiveness of the current surveillance strategy. We also reviewed critical strategies and new technologies which could improve dysplasia detection. RECENT FINDINGS: Adherence to the current EGD surveillance guidelines is suboptimal with high rates of missed dysplasia/EAC. The influence of surveillance on EAC mortality appears modest. Careful cleansing, inspection and sampling of the BE mucosa using high resolution while light and (electronic) chromoendoscopy is critical. Newer sampling techniques coupled with computer aided diagnosis and emerging imaging technologies have shown promise in improving dysplasia detection. Personalized surveillance with risk stratification based on risk factors for progression may be on the horizon. SUMMARY: Current BE surveillance strategy will likely be further refined and optimized by emerging new technologies in tissue sampling, advanced imaging and risk stratification.
PURPOSE OF REVIEW: There is conflicting data on the effectiveness of the currently recommended endoscopic surveillance strategy in non-dysplastic BE patients. We reviewed the literature to evaluate the (cost) effectiveness of the current surveillance strategy. We also reviewed critical strategies and new technologies which could improve dysplasia detection. RECENT FINDINGS: Adherence to the current EGD surveillance guidelines is suboptimal with high rates of missed dysplasia/EAC. The influence of surveillance on EAC mortality appears modest. Careful cleansing, inspection and sampling of the BE mucosa using high resolution while light and (electronic) chromoendoscopy is critical. Newer sampling techniques coupled with computer aided diagnosis and emerging imaging technologies have shown promise in improving dysplasia detection. Personalized surveillance with risk stratification based on risk factors for progression may be on the horizon. SUMMARY: Current BE surveillance strategy will likely be further refined and optimized by emerging new technologies in tissue sampling, advanced imaging and risk stratification.
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: Anna Tavakkoli; Henry D Appelman; David G Beer; Chaitra Madiyal; Maryam Khodadost; Kimberly Nofz; Val Metko; Grace Elta; Thomas Wang; Joel H Rubenstein Journal: Clin Gastroenterol Hepatol Date: 2018-02-09 Impact factor: 11.382
Authors: Tusar K Desai; Kumar Krishnan; Niharika Samala; Jashanpreet Singh; John Cluley; Subaiah Perla; Colin W Howden Journal: Gut Date: 2011-10-13 Impact factor: 23.059